In various published series, 32%-100% of women with von Willebrand disease (VWD
), the most common inherited bleeding disorder, were reported to have heavy menstrual bleeding.
In general, most patients with vWD
do not require prophylactic replacement therapy, especially for Type 1 disease or if the ristocetin cofactor levels are more than 50% of normal.
It has previously been shown that amino acid substitutions R1306W, R1308C, V1316M, and R1341Q account for 90% prevalence of the subtype 2B VWD
epistaxis particularly lasting for more than 30 min, causing anaemia or hospital admission seen in platelet disorders, VWD
(Grade C, level IV).
Willfact is a plasma-derived human von Willebrand factor (vWF) concentrate used to stop and prevent bleeding in severe vWD
Using our standard test processes for VWD
investigation and LTA without adjustment of PRP platelet count, 2/9 (22%) of these cases were identified to have possible mild platelet dysfunction, 1/9 (11%) possible mild type 1 VWD
, and 1/9 (11%) possible mild type 1 VWD
plus moderate platelet dysfunction.
The signal from the VWD
detector was fed directly to the agilent data acquisition system.
From an epidemiologic standpoint, the clinical course of the disease (3 weeks), age of affected pigs (<3 weeks), and clinical signs were in agreement with those of VWD
caused by PHE-CoV (3,8,13).
Erik von Willebrand first described inherited von Willebrand disease (vWD
) in 1926, when he documented an autosomal-dominant pattern of inheritance of excessive bleeding (as opposed to X-linked transmission that characterises the common 2 types of haemophilia) in a family from the Aland Islands in the Gulf of Bothnia.
This clotting factor concentrate is the first biologic product approved for patients with von Willebrand disease (vWD
) who are undergoing surgery or invasive procedures and for whom desmopressin is either ineffective or contraindicated, according to the FDA.
* Special Considerations: The product is not approved for people with severe vWD
(type 3) undergoing major surgery.
However, with the introduction of new Medicare/Medicaid "dual eligible" plans and the increasing diagnoses of blood illnesses such as von Willebrand disease (vWD
), a blood clotting disease, MA plans may see increasing claims in this area.